article Open AccessTop 1% cited

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Journal of Clinical Oncology · 2009 · Vol. 27(34) · pp. 5794–5799

Daniel Y.C. Heng✉(Dana-Farber Cancer Institute)Wanling Xie(Dana-Farber Cancer Institute)Meredith M. Regan(Dana-Farber Cancer Institute)Mark Warren(Dana-Farber Cancer Institute)Ali Golshayan(Dana-Farber Cancer Institute)Chakshu Sahi(Dana-Farber Cancer Institute)Bernhard J. Eigl(Dana-Farber Cancer Institute)Joseph D. Ruether(Dana-Farber Cancer Institute)Tina Cheng(Dana-Farber Cancer Institute)Scott North(Dana-Farber Cancer Institute)Peter Venner(Dana-Farber Cancer Institute)Jennifer J. Knox(Dana-Farber Cancer Institute)Kim N.(Dana-Farber Cancer Institute)Christian Kollmannsberger(Dana-Farber Cancer Institute)David F. McDermott(Dana-Farber Cancer Institute)William Oh(Dana-Farber Cancer Institute)Michael B. Atkins(Dana-Farber Cancer Institute)Ronald M. Bukowski(Dana-Farber Cancer Institute)Brian I. Rini(Dana-Farber Cancer Institute)Toni K. Choueiri(Dana-Farber Cancer Institute)

View via DOI Full-text PDF

Abstract

This model validates components of the MSKCC model with the addition of platelet and neutrophil counts and can be incorporated into patient care and into clinical trials that use VEGF-targeted agents.

Renal cell carcinoma treatment Vascular Tumors and Angiosarcomas Ferroptosis and cancer prognosisMedicineSunitinibRenal cell carcinomaInternal medicineBevacizumabSorafenibProportional hazards modelCohortAdverse effectOncology

MeSH terms

BevacizumabSorafenibSunitinibAgedAntibodies, MonoclonalAntineoplastic AgentsBenzenesulfonatesCarcinoma, Renal CellFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedNiacinamide

Citations

2,104

FWCI

42.78

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Treatment of renal cell carcinoma: Current status and future directions